Sign in Subscribe

Andrew Ninh

Navigating the Impact of Semaglutide (GLP-1) on Health Plans and Risk-Bearing Entities

Navigating the Impact of Semaglutide (GLP-1) on Health Plans and Risk-Bearing Entities

By Andrew Ninh In the realm of U.S. healthcare, the arrival of Semaglutide and other GLP-1s has triggered a cascade of responses among varied stakeholders. These drugs present a game-changer in treating diabetes and obesity, requiring a detailed exploration of their implications on diverse health plans and risk-bearing entities,

State of Biosimilars in 2023 and Looking Ahead to 2024

State of Biosimilars in 2023 and Looking Ahead to 2024

As 2023 draws to a close, the world of pharmaceuticals is abuzz with the transformative potential of biosimilars. Unlike traditional generic drugs, which are exact replicas of small-molecule branded medications, biosimilars are near-copies of complex biologic drugs produced by different manufacturers. The burgeoning biosimilar market in the U.S. is

Welcome to CuraFi

Welcome to CuraFi

Hello and welcome to CuraFi's inaugural blog post! At the heart of Silicon Valley, we are sculpting the future of healthcare by revolutionizing the way society addresses the financial challenges of high-cost therapeutics. In an age where groundbreaking treatments often come with multi-million dollar price tags, it'